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INTRODUCTION
Traditionally, the risk group of early stages (stage
IB-IIA) cervical cancer after radical hysterectomy
(RH) and pelvic lymph node dissection (PLND) is
divided into two based on the prognostic factors
associated with the risk of recurrence which is
Abstract
Objective: To evaluate the benefits of adjuvant radiotherapy (ART)
based on Kartu Delgado (simple form of Gynecologic Oncology
Group (GOG) scoring system) aimed at women with early stage cer-
vical cancer after radical surgery.
Method: Fifty patients were enrolled for this study. Twenty one pa-
tients from 2011-2012 were given ART following surgery based on
their Kartu Delgado score from as follows: score <120 were desig-
nated for observation; score >120 were given ART. Their score and
recurrence were compared with 29 patients who were treated in
2009-2010 (based on single prognostic factor).
Result: We observed eighteen recurrences for the duration this
study. Thirteen patients from the period of 2009-2010 and five pa-
tients from the period of 2011-2012. Most recurrences occurred in
patients from 2009-2010 with score > 120 but were not designated
ART. Two-years recurrence-free survival (RFS) for subjects with
score <120 who were designated observation was 76.23% while for
score >120 with ART was 64.29%.
Conclusion: Adjuvant radiotherapy given based on Kartu Delgado
reduced the number of recurrences in women with stage IB-IIA cer-
vical cancer after treated by surgery.
[Indones J Obstet Gynecol 2014; 3: 146-152]
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Abstrak
Tujuan: Mengevaluasi manfaat pemberian radiasi ajuvan yang ber-
basiskan Kartu Delgado pada pasien kanker serviks stadium dini pas-
capembedahan.
Metode: Lima puluh pasien diikutsertakan dalam penelitian ini. Dua
puluh satu pasien menerima radiasi ajuvan pascapembedahan ber-
dasarkan skor yang didapat dengan ketentuan sebagai berikut: skor
<120 pasien diobservasi sedangkan skor >120 maka pasien diberi ra-
diasi ajuvan. Skor dan kekambuhannya dibandingkan dengan 29 ka-
sus dari periode 2009-2010 yang ditatalaksana berbasiskan satu fak-
tor prognostik.
Hasil: Delapan belas kekambuhan terjadi pada penelitian ini. Tiga belas
pasien yang mengalami kekambuhan berasal dari periode 2009-2010
dan lima pasien kambuh berasal dari periode 2011-2012. Kekambuhan
tertinggi (50%) berasal dari periode 2009-2010 pada pasien dengan
skor >120 tetapi tidak dilakukan radiasi ajuvan. Kesintasan 2-tahun be-
bas kekambuhan pada skor <120 di mana dilakukan observasi adalah
76,23% sedangkan kesintasan 2-tahun bebas kekambuhan untuk skor
>120 di mana diberikan radioterapi ajuvan adalah 64,29%.
Kesimpulan: Pemberian radioterapi ajuvan berdasarkan Kartu Del-
gado mengurangi kekambuhan pada pasien kanker serviks stadium
IB-IIA pascapembedahan.
[Maj Obstet Ginekol Indones 2014; 3: 146-152]
Kata kunci: faktor prognostik, histerektomi radikal, kanker serviks,
risiko menengah
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high-risk groups (with lymph nodes metastases
(LNM)) and non-high-risk groups (without LNM).
Previously, adjuvant radiotherapy (ART) is only in-
dicated for high-risk groups. Next is non-high-risk
groups (without LNM) where the name is later
changed into intermediate-risk group.1 The prob-
lems arising in the intermediate-risk group who do
not receive ART is the presence of recurrence. On
the other hand, there are difficulties in determining
the intermediate-risk group requiring ART, whe-
ther only one prognostic factor is enough as an in-
dication for ART or a combination of prognostic
factors is needed.
In its recent definition, high-risk group is not
limited only to cases with LNM but also para-
metrial invasion and positive surgical margin.2
Sedlis et al introduced the term intermediate-risk
and utilized three prognostic factors, namely lym-
phovascular space invasion (LVSI), tumor size and
depth of stromal invasion (DSI).1 Gynecologic On-
cology Group (GOG) pioneered by Delgado et al
combined those three factors and make the GOG
scoring system. They found that a score higher
than 120 without ART correlated with a 41% re-
currence rate.3 Rushdan et al reported that a score
higher than 120 after ART showed a recurrence
rate of 7.1% (1 out of 14 patients).4
Controversy on the indication of ART occurs due
to a lack of standardization criteria for receiving
ART. Research on the assessment of cervical cancer
prognostic factor and the role of ART on cervical
cancer patients provided varying results in each
oncology centers. These results are difficult to com-
pare because of differences in patient selection.
This is our first experience to determine if there
is an improvement in outcome when the indication
for ART is based on Kartu Delgado (simple form of
GOG scoring system). Thus, the aim of this study is
to evaluate the treatment outcomes and confirm
the applicability of combination prognostic factor
(Kartu Delgado) instead of single prognostic factor
as indication for ART.
METHODS
This study was approved by the Institutional Ethics
Committee of Universitas Indonesia, dr. Cipto Ma-
ngunkusumo hospital, Jakarta. We enrolled 50 pa-
tients with stage IB1 to IIA2 intermediate-risk
group cervical cancer post-RH and PLND during
the period of January 2009 until December 2012.
Patients with histopathological findings that show-
ed negative LNM, negative parametrial invasion
and clear surgical margins were included in the
study. Patients with neuroendocrine histopatho-
logy and cervical cancer patients accompanied by
presence of other cancer were excluded from the
study. Design used in this study was ambispective
cohort. We observed the 2009-2010 period with a
historical cohort design (ART designation based on
single prognostic factor) and the period of 2011-
2012 with a prospective cohort design (ART de-
signation based on Kartu Delgado). For period of
January 2009 until December 2010, medical re-
cords were reviewed retrospectively and the fol-
lowing parameters were collected: FIGO stage, tu-
mor size, DSI, LVSI, adjuvant treatment, date of sur-
gery and date of recurence or last follow-up.
Depth of stromal invasion was measured in mil-
limeters and fractional thickness of the cervix di-
vided into thirds (superficial, middle and deep).3
DSI was measured as the maximum perpendicular
distance from the basement membrane to the
outer tumor surface.5 DSI measurement was taken
from the base of the epithelium from which the
carcinoma arises to the deepest point of inva-
sion.6,7 For tumor size, we measured the greatest
diameter of the tumor on the postoperative speci-
men before it was preserved with formaldehyde.8
LVSI was considered positive when neoplastic cells
were seen within endothelium-lined spaces.3,5,9
All slides were re-evaluated using hematoxylin
and eosin (H&E) staining to analyze DSI and LVSI
by expert pathologist. Subsequently, the score was
calculated using Kartu Delgado (Figure. 1). Firstly,
we circle the size of the tumor and the LVSI status
then pull a downward line. Next, the number cor-
responding to the DSI is circled and a horizontal
line is drawn from there. The intersect of these two
lines is the score. Patients with a score higher than
120 were given ART while patients with a score
lower than 120 were not given ART and only ob-
served.
All designated patient treatment were approved
by our tumor board, and patients also provided
written informed consent. Adjuvant radioterapy
was given in the form of external beam radiothe-
rapy (EBRT) alone started within four weeks after
surgery. EBRT was delivered to the whole pelvis
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(standard field) in 2.00 Gy fractions once daily for
5 days per week. At the time of follow-up, patients
were categorized as no evidence of disease if there
were no suspicion of recurrence.10 Patients were
evaluated by anamnesis, pelvic and bimanual exa-
mination, and ultrasonography every three months
during the first two years of follow-up. Patients
who did not come for follow up, were contacted
via telephone to come for follow up.11
All data was stored using Microsoft Excel and
the statistical analyses performed using Stata ver-
sion 12. Bivariate analyses were calculated using
Pearson’s chi-square and Fisher’s exact test. Pro-
bability was considered significant if p value <0,05
with confidence interval 95%. Correlation between
Kartu Delgado score and recurrence-free interval
(RFI) were evaluated with Pearson correlation test.
Recurrence-free survival (RFS) was calculated
from the date of surgery to recurrence or the latest
date of follow-up using Kaplan Meier. Survival dif-
ferences were tested by the log rank test.
RESULTS
During the research period there were 18 cases of
recurrences. During the 2009-2010 period, indica-
tion for ART is only based on single prognostic fac-
tor (moderate-poor differentiation, adenocarcino-
ma type, positive LVSI and large tumor size) and
there were thirteen cases (72.22%) of recurrence.
During the period of 2011-2012, ART was desig-
nated based on Kartu Delgado and five (27.78%)
cases of recurrence were identified. The clinicopa-
thologic characteristics of intermediate-risk group
are summarized in Table 1. Ten cases of recur-
rence, occurred at score of more than 120 managed
with observation (8 cases from the 2009-2010 pe-
riod).
Figure 1. How to Use Kartu Delgado.
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Among the clinicopathologic factors analyzed in
this study, only Kartu Delgado is significantly re-
lated to recurrence. Bivariate analysis revealed that
Kartu Delgado provided a risk ratio (RR) of 2.91,
with 95% confidence interval (CI) 1.43 to 5.90 and
p=0.003. No significant relation was identified be-
tween recurrence and tumor size, LVSI, histologic
subtype, and differentiation as a single prognostic
factor. Relation of clinicopathologic factors as sin-
gle prognostic factor and combination prognostic
factor is presented in Table 2. The management
given to the patients may be consistent or incon-
sistent with the management indicated by the
prognostic factors, as indicated in Table 2.
To determine the correlation between Kartu
Delgado scores with RFI, we created a scatterplot
(Figure. 2) and analyzed using a Pearson correla-
tion test (p = 0.0003). The correlation was found
to be negative, meaning the higher the score, RFI
will be declined.
 Our data showed survival between 2009-2010
period and 2011-2012 period, an estimated two-
years RFS of single prognostic factor was 55.56%
and by using Kartu Delgado was 77.5%. Survival
between a score <120 and score >120, an esti-
mated 2-years RFS for score >120 was 43.78%,
while for score <120 was 78.03%. Survival of each
management as assigned using Kartu Delgado
could be stratified into four groups, as seen in Fig-
ure 3. The estimated 2-years RFS for score <120
with ART was 100%, 76.23% for score <120 with
observation, 64.29% for score >120 with ART and
30.77% for score >120 with observation.
Table 1. Baseline Characteristics of Intermediate-Risk Group.
Characteristic
Event of recurrence (n=50)
NED
32 (100%)
Recurrence
18 (100%)
Univariate
p-value
Stage
(FIGO 2009)
IB1
IB2
IIA1
IIA2
25 (78.13%)
1 (3.13%)
5 (15.63%)
1 (3.13%)
7 (38.89%)
7 (38.89%)
4 (22.22%)
0 (0%)
0.005
Kartu Delgado score < 120
> 120
23 (71.88%)
9 (28.13%)
6 (33.33%)
12 (66.67%)
0.008
Histologic subtype Squamous cell carcinoma (SCC)
Adenocarcinoma
Adenosquamous carcinoma
21 (65.63%)
 7 (21.88%)
 4 (12.50%)
10 (55.56%)
7 (38.89%)
1 (5.56%)
0.380
Tumor size
  4 cm
> 4 cm
30 (93.75%)
2 (6.25%)
11 (61.11%)
7 (38.89%)
0.004
LVSI Negative
Positive
22 (68.75%)
10 (31.25%)
12 (66.67%)
6 (33.33%)
0.880
Differentiation Well
Moderate
Poor
7 (21.88%)
19 (59.38%)
6 (18.75%)
2 (11.11%)
13 (72.22%)
3 (16.67%)
0.587
Adjuvant Treatment Observation
Adjuvant Radiotherapy
24 (75%)
8 (25%)
16 (88.89%)
2 (11.11%)
0.239
Period 2009-2010
2011-2012
14 (43.75%)
18 (56.25%)
13 (72.22%)
5 (27.78%)
0.053
NED = no evidence of disease
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Figure 3. Survival Based on Kartu Delgado and Manage-
ment.
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Figure 2. Correlation of Kartu Delgado score with RFI.
Score  < 120 (Adjuvant Radiation)
Score < 120 (Observation)
Score > 120 (Ad juvant Rad iation)
Score > 120 (Observa tion)
Log rank tes; p=0,0010
2
0
4
0
6
0
8
0
1
0
0
%
 S
u
rv
iv
a
l
0 6 12 18 24 30 36 42 48 54 60
Reccurence-free survival (months)
Score < 12 0 (Observation) Score < 12 0 (Adjuvant Ra diation)
Score > 12 0 (Adjuvant Ra diation ) Score > 12 0 (Observation)
Table 2. Bivariate Analysis of Clinicopathologic Factor (Kartu Delgado vs Single Prognostic Factor) Related to Recurrence.
Clinicopathologic
Factor (Management)
Event of recurrence Total
p RR 95%CI
NED
n (%)
Recurrence
n (%)
Consistent Kartu Delgado
Score <120 (Observation)
Score >120 (ART)
27 (77.14%) 8 (22.86%) 35 (100%) 0.003 2.91 1.43-5.90
Inconsistent Kartu Delgado
Score <120 (ART)
Score >120 (Observation)
5 (33.33%) 10 (66.67%) 15 (100%)
Consistent single prognostic factor (tumor size)
<4 cm (Observation)
>4 cm (ART)
24 (68.57%) 11 (31.43%) 35 (100%) 0.304 1.48 0.71-3.07
Inconsistent single prognostic factor
<4 cm (ART)
>4 cm (Observation)
8 (53.33%) 7 (46.67%) 15 (100%)
Consistent single prognostic factor (LVSI)
LVSI negative (Observation)
LVSI positive (ART)
24 (66.67%) 12 (33.33%) 36 (100%) 0.529 1.28 0.60-2.75
Inconsistent single prognostic factor
LVSI negative (ART)
LVSI positive (Observation)
8 (57.14%) 6 (42.86%) 14 (100%)
Consistent single prognostic factor
(Histologic subtype)
SCC (Observation)
Non SCC (ART)
15 (60%) 10 (40%) 25 (100%) 0.556 0.80 0.37-1.68
Inconsistent single prognostic factor
SCC (ART)
Non SCC (Observation)
17 (68%) 8 (32%) 25 (100%)
Consistent single prognostic factor
(Differentiation)
Well-Moderate (Observation)
Poor (ART)
24 (61.54%) 15 (38.46%) 39 (100%) 0.72* 0.70 0.24-2.01
Inconsistent single prognostic factor
Well-Moderate (ART)
Poor (Observation)
8 (72.73%) 3 (27.27%) 11 (100%)
*Fisher exact
ART=Adjuvant Radiotherapy; SCC=squamous cell carcinoma; LVSI=lymphovascular space invasion; RR=risk ratio
NED = no evidence of disease
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DISCUSSION
The purpose of this study is to evaluate recurrence
among intermediate-risk stage IB-IIA cervical can-
cer after RH and PLND with application of Kartu
Delgado as indication for ART. This study answers
the question whether single factor prognostic is re-
liable as indication for ART or a combination of
prognostic factors is required. In this study we
combined three prognostic factors, namely DSI, tu-
mor size and LVSI. We were able to demonstrate
that the use of single prognostic factor as indication
of ART has weaknesses in predicting the recur-
rence. For example in cases with negative LVSI, DSI
and tumor size as prognostic factors actually have
an important role in determining whether ART is
required or not. This is clearly seen in the scoring
system of Kartu Delgado where each prognostic
factor plays a role in determining the score and
each patient has her own score, although they are
at the same stage (IB-IIA). Perhaps, this will explain
the difference in survival among intermediate-risk
groups.
In this study, we discovered that Kartu Delgado
score is significantly related (p=0.003) with recur-
rence. Delgado et al reported that score >120 and
managed with observation is related to a recur-
rence rate of 41%.3 Our data showed that score
>120 managed with observation only is related to
a recurrence rate of 76.9%. Meanwhile when pa-
tients scoring >120 was managed with ART the re-
currence rate was reduced by 51.9% to 25%. Even-
though there are no recurrences in patients with
score <120 assigned to ART, it should be noted that
their actual score were less than 40 (these patients
were given ART due to poor diferentiation and
non-SCC histologic subtype). Rushdan et al and Yeo
et al found that for cases with scores less than 40
with observation there were also no recurren-
ces.4,11
We found the correlation between Kartu Del-
gado score with RFI to be clinically and statistically
significant (p=0.0003). To our knowledge, this is
the first report showing a significant correlation of
a scoring system with RFI. We also observed no
relationship between the large tumor size, positive
LVSI, moderate-poor differentiation and adenocar-
cinoma type histopathology as a single prognostic
factor for recurrence. Use of a single prognostic fac-
tor as indication for ART is not able to predict re-
currence.
Our results were similar with several other stud-
ies. Rutledge et al stated that cervical cancer prog-
nosis is affected by LVSI and DSI, not just tumor
size as the criteria to determine stage IB1 and
IB2.12 A surgical approach to stratify patients’ risk
based on surgical-pathologic information such as
LVSI and DSI would seem to be a reasonable treat-
ment approach. Memarzadeh et al reported that
presence of LVSI alone was not a predictor of pelvic
nodal disease.13 Cervical LVSI in combination with
parametrial LVSI was predictive of metastatic dis-
ease (p<0.001). Depth of invasion within the cer-
vical stroma was associated with parametrial LVSI.
It was concluded that LVSI and DSI in combination
is prognostic for LNM. Zaino et al reported that de-
gree of differentiation as a prognostic factor cannot
stand alone.14 Its combination with DSI and LVSI
is essential and should be reported routinely. At
the early stages of cervical cancer there is no sig-
nificant difference in survival between squamous
cell carcinoma and adenocarcinoma. Ayhan et al
added that histopathologic type is not a prognostic
factor for early stage cervical cancer with no re-
ported LNM.15
Most recurrence of cervical cancer occurs within
the first two years after surgery.16 Monk et al re-
ported that recurrence within 24 months after sur-
gery is as high as 88%.17 Likewise, Reis et al ob-
served the rate of recurrence within 24 months af-
ter RH to be about 89%.18 Pieterse et al found a
lower recurrence rate of about 63% within 24
months post-surgery.19
Samlal et al found that patients without LNM has
a 5-year survival rate of around 90%, compared to
50%-65% in patients with LNM.20 Our study ob-
tained a survival rate of 30.77% in patients who
should have received ART (score >120) but did not
receive ART. Survival rate was found to reach
64.29% when high-risk group with a score >120
received ART. For the intermediate-risk group with
a score <120 managed with observation only, the
survival rate was 76.23%. The difference in sur-
vival rate in our study with Samlal et al lies in the
indication of ART. They have used a combination
of prognostic factors as indication for ART and not
only based on a single prognostic factor.
The fact is that although cervical cancer is theo-
retically preventable and one of the most curable
human cancers, recurrences are unavoidable. Hen-
ce, the management of cervical carcinoma remains
to be the most challenging in gynecologic oncology.
The outcome of cervical carcinoma is related to
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certain prognostic factors. Many centers have em-
phasized the necessity of individualized treatment
according to a combination of clinicopathologic fac-
tors. The score points assigned to each prognostic
factor will give a better prediction of recurrence
and produce better results in planning for adjuvant
therapy. It is expected that by using scoring system
in determining assignment of ART, the recurrence
rate will be reduced.
In conclusion, ART in intermediate-risk group with
a score >120 (based on Kartu Delgado) can reduce
recurrence significantly. RFI for intermediate-risk
group risk have a negative linear correlation with
Kartu Delgado score. Instead of a single prognostic
factor, we recommend the use of combination prog-
nostic factors as an indication for ART.
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